Remarkable achievement: The National Medical Products Administration of China granted CanSino approval for its inhaled vaccine to be used as a booster dose. CONVIDECIA was found to have 58% efficacy against symptomatic disease and 92% against severe COVID-19.
.jpg)
.jpg)
CanSinoBIO's Convidecia Air™ Receives Approval in China
2022-09
.jpg)
CanSino Biologics Inc. (“CanSinoBIO”) (SSE: 688185, HKEX: 06185) announced that the National Medical Products Administration of China (“NMPA”) has granted the Company approval for its Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation (trade name: Convidecia Air™) to be used as a booster dose.
.jpg)
Utilizing the same adenovirus vector technological platform as the intramuscular version Convidecia™, Convidecia Air™ provides a non-invasive option that uses a nebulizer to change liquid into an aerosol for inhalation through the mouth. Convidecia Air™ is needle-free and can effectively induce comprehensive immune protection in response to SARS-CoV-2 after just one breath.
.jpg)
CanSinoBIO received the approval of its clinical trial application for Convidecia Air™ in March 2021. Studies published in The Lancet indicated that Convidecia Air™ can induce strong humoral, cellular and mucosal immunity to achieve triple protection and effectively contain the infection and spread of the virus.
Currently, CanSinoBIO has achieved steady production of various innovative vaccines and established a global supply chain, with a goal to continue to make quality vaccine products more accessible by the global population.
WHO validates 11th vaccine for COVID-19
.jpg)
Today, the World Health Organization (WHO) issued an emergency use listing (EUL) for CONVIDECIA, a vaccine manufactured by CanSino Biologics, China, adding to a growing portfolio of vaccines validated by WHO for the prevention of COVID-19 caused by SARS-CoV-2.
WHO’s
EUL procedure assesses the quality, safety and efficacy of COVID-19
vaccines as a prerequisite for COVAX vaccine supply. It also allows
countries to expedite their own regulatory approval to import and
administer COVID-19 vaccines.
CONVIDECIA was assessed under
the WHO EUL procedure based on the review of data on quality, safety,
efficacy, a risk management plan, programmatic suitability and a
manufacturing site inspection conducted by WHO. The Technical Advisory
Group for Emergency Use Listing, convened by WHO and made up of
regulatory experts from around the world, has determined that the
vaccine meets WHO standards for protection against COVID-19 and that the
benefits of the vaccine far outweigh risks.
CONVIDECIA is
based on a modified human adenovirus that expresses the spike S protein
of SARS-CoV-2. It is administered as a single dose.
CONVIDECIA was
also reviewed earlier this month by WHO’s Strategic Advisory Group of
Experts on Immunization (SAGE), which formulates vaccine specific
policies and recommendations for vaccines’ use in populations (i.e.
recommended age groups, intervals between shots, specific groups such as
pregnant and lactating women).
The SAGE recommends use of the vaccine as a single (0.5ml) dose, in all age groups 18 and above.
CONVIDECIA was found to have 58% efficacy against symptomatic disease and 92% against severe COVID-19.
China approves inhaled Covid vaccine
Made by CanSino, it has similar ingredients to its injected vaccine, using a harmless adenovirus as a carrier for the genetic code that teaches the body how to fight Covid.
Inhaled as a fine mist, Convidecia Air can provide good protection after just one breath, the company says.
Other researchers, including teams in the UK and the US, have been investigating nasal spray vaccines.
Scientists say these may give added immunity in the lining of the nose and upper airways, where Covid typically enters the body.
RELATED CONTENT
No comments:
Post a Comment